Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Torrent

Drug and asset intelligence for Torrent with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Stage: Development stage unavailable

Sponsor company

Torrent Pharmaceuticals →

Recent signals(6)

StrategyAugust 5, 2026

Torrent's Rosuvastatin Calcium ANDA Receives Approval Status

Torrent's ANDA201619 for Rosuvastatin Calcium has received an approval status (AP) from the FDA.

RegulatoryJuly 24, 2026

Torrent's Moxifloxacin Hydrochloride ANDA Receives Approval Status

Torrent's ANDA for Moxifloxacin Hydrochloride has received an approval status (AP) from the FDA.

StrategyJuly 24, 2026

Torrent Pharmaceuticals receives AP status for Metformin Hydrochloride ANDA079226

Torrent Pharmaceuticals has received an Abbreviated Approval (AP) for their ANDA079226 for Metformin Hydrochloride.

StrategyJuly 24, 2026

Torrent's Metformin Hydrochloride ANDA090014 Receives AP Status

Torrent's ANDA for Metformin Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

StrategyJuly 23, 2026

Torrent Pharmaceuticals receives AP status for Metformin Hydrochloride ANDA077711

Torrent Pharmaceuticals has received an Abbreviated Approval (AP) for their ANDA077711 application for Metformin Hydrochloride.

CompetitiveJune 10, 2026

Torrent's Lurasidone Hydrochloride ANDA Receives AP Status from FDA

Torrent's ANDA for Lurasidone Hydrochloride has received an Abbreviated Approval (AP) status from the FDA.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Infectious Disease →

Therapeutic areas

Antipsychotic →

Cardiovascular →

Infectious Disease →

Oral Hypoglycemic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.